Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919670 · ClinicalTrials.gov registry record · NA
A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 114
- Enrollment target
NCT02919670 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 114 participants.
The verdict
NCT02919670, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 114 participants
- Enrollment target
Study Summary
This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant. The following interventions will be involved in this study: * Enterade plus standard supportive care * Placebo plus standard supportive care. The placebo will be a mixture of water, electrolytes, and sweetener.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Enterade
- OTHER Standard Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02919670
The ClinicalTrials.gov registry entry for NCT02919670 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02919670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02919670 about?
NCT02919670 is a clinical study titled "A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma". This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant. The following interventions will be involved in this study: * Enterade plus standard supportive care * Placebo plus standard supportive care. The placebo will be a...
What is the current status of trial NCT02919670?
This trial is currently completed. It is a NA study. The enrollment target is 114 participants. The study started on 2016-10. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02919670?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Enterade (DIETARY_SUPPLEMENT), Standard Supportive Care (OTHER).
Who is sponsoring clinical trial NCT02919670?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.